SG/CALL/ELI LILLY & CO/480/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 15:44:34 2024-06-28 EDT | ||
| 41.47 EUR | +0.61% |
|
| Current month | +26.66% | ||
| 1 month | +31.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 41.47 | +0.61% |
| 24-06-27 | 41.22 | +0.91% |
| 24-06-26 | 40.85 | +0.12% |
| 24-06-25 | 40.8 | +2.20% |
| 24-06-24 | 39.92 | +1.89% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:44 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV4QH0 |
| ISIN | DE000SV4QH02 |
| Date issued | 2023-04-25 |
| Strike | 480 $ |
| Maturity | 2025-01-17 (202 Days) |
| Parity | 10 : 1 |
| Emission price | 3.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 41.99 € |
|---|---|
| Lowest since issue | 2.81 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
